Declared Dividend • Jun 17
Dividend increased to CN¥0.88 Dividend of CN¥0.88 is 26% higher than last year. Ex-date: 22nd June 2026 Payment date: 22nd June 2026 Dividend yield will be 5.7%, which is higher than the industry average of 1.9%. Sustainability & Growth Dividend is not adequately covered by earnings (96% earnings payout ratio) nor is it covered by cash flows (160% cash payout ratio). The dividend has increased by an average of 22% per year over the past 10 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to grow by 6.6% to bring the payout ratio under control. EPS is expected to grow by 29% over the next 3 years, which is sufficient to bring the dividend into a sustainable range. Buy Or Sell Opportunity • May 26
Now 22% overvalued Over the last 90 days, the stock has fallen 6.1% to CN¥23.37. The fair value is estimated to be CN¥19.12, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 12%. Revenue is forecast to grow by 23% in 2 years. Earnings are forecast to grow by 21% in the next 2 years. Announcement • May 18
China Resources Jiangzhong Pharmaceutical Co.,Ltd, Annual General Meeting, Jun 05, 2026 China Resources Jiangzhong Pharmaceutical Co.,Ltd, Annual General Meeting, Jun 05, 2026, at 14:00 China Standard Time. Location: The Company's Meeting Room, Nanchang, Jiangxi China Reported Earnings • Apr 25
First quarter 2026 earnings: EPS exceeds analyst expectations while revenues lag behind First quarter 2026 results: EPS: CN¥0.46 (up from CN¥0.45 in 1Q 2025). Revenue: CN¥1.04b (down 13% from 1Q 2025). Net income: CN¥288.0m (up 1.1% from 1Q 2025). Profit margin: 28% (up from 24% in 1Q 2025). The increase in margin was driven by lower expenses. Revenue missed analyst estimates by 15%. Earnings per share (EPS) exceeded analyst estimates by 1.1%. Revenue is forecast to grow 9.0% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth. Announcement • Mar 30
China Resources Jiangzhong Pharmaceutical Co.,Ltd to Report Q1, 2026 Results on Apr 25, 2026 China Resources Jiangzhong Pharmaceutical Co.,Ltd announced that they will report Q1, 2026 results on Apr 25, 2026 Reported Earnings • Mar 20
Full year 2025 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2025 results: EPS: CN¥1.43 (up from CN¥1.25 in FY 2024). Revenue: CN¥4.22b (down 4.9% from FY 2024). Net income: CN¥906.7m (up 15% from FY 2024). Profit margin: 22% (up from 18% in FY 2024). The increase in margin was driven by lower expenses. Revenue missed analyst estimates by 8.7%. Earnings per share (EPS) exceeded analyst estimates by 3.6%. Revenue is forecast to grow 8.2% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 12% per year whereas the company’s share price has increased by 15% per year. Reported Earnings • Jan 24
Full year 2025 earnings released: EPS: CN¥1.43 (vs CN¥1.25 in FY 2024) Full year 2025 results: EPS: CN¥1.43 (up from CN¥1.25 in FY 2024). Revenue: CN¥4.22b (down 4.9% from FY 2024). Net income: CN¥906.1m (up 15% from FY 2024). Profit margin: 22% (up from 18% in FY 2024). The increase in margin was driven by lower expenses. Revenue is forecast to grow 14% p.a. on average during the next 2 years, compared to a 14% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 12% per year whereas the company’s share price has increased by 16% per year. Announcement • Dec 26
Jiang Zhong Pharmaceutical Co.,Ltd to Report Fiscal Year 2025 Results on Mar 20, 2026 Jiang Zhong Pharmaceutical Co.,Ltd announced that they will report fiscal year 2025 results on Mar 20, 2026 Reported Earnings • Oct 25
Third quarter 2025 earnings: EPS in line with expectations, revenues disappoint Third quarter 2025 results: EPS: CN¥0.26 (up from CN¥0.23 in 3Q 2024). Revenue: CN¥792.1m (flat on 3Q 2024). Net income: CN¥161.1m (up 11% from 3Q 2024). Profit margin: 20% (up from 18% in 3Q 2024). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 12% per year and the company’s share price has also increased by 12% per year. Declared Dividend • Oct 01
First half dividend of CN¥0.50 announced Shareholders will receive a dividend of CN¥0.50. Ex-date: 13th October 2025 Payment date: 13th October 2025 Dividend yield will be 5.5%, which is higher than the industry average of 1.9%. Sustainability & Growth Dividend is not adequately covered by earnings (94% earnings payout ratio) nor is it covered by cash flows (120% cash payout ratio). The dividend has increased by an average of 24% per year over the past 10 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to grow by 3.9% to bring the payout ratio under control. EPS is expected to grow by 41% over the next 3 years, which is sufficient to bring the dividend into a sustainable range. Announcement • Sep 30
Jiang Zhong Pharmaceutical Co.,Ltd to Report Q3, 2025 Results on Oct 25, 2025 Jiang Zhong Pharmaceutical Co.,Ltd announced that they will report Q3, 2025 results on Oct 25, 2025 Reported Earnings • Aug 22
Second quarter 2025 earnings: EPS and revenues miss analyst expectations Second quarter 2025 results: EPS: CN¥0.37 (up from CN¥0.35 in 2Q 2024). Revenue: CN¥957.0m (up 1.3% from 2Q 2024). Net income: CN¥237.4m (up 7.0% from 2Q 2024). Profit margin: 25% (up from 24% in 2Q 2024). Revenue missed analyst estimates by 8.9%. Earnings per share (EPS) also missed analyst estimates by 4.3%. Revenue is forecast to grow 10.0% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 11% per year whereas the company’s share price has increased by 12% per year. Announcement • Jun 30
Jiang Zhong Pharmaceutical Co.,Ltd to Report First Half, 2025 Results on Aug 22, 2025 Jiang Zhong Pharmaceutical Co.,Ltd announced that they will report first half, 2025 results on Aug 22, 2025 Declared Dividend • Jun 18
Dividend of CN¥0.70 announced Shareholders will receive a dividend of CN¥0.70. Ex-date: 20th June 2025 Payment date: 20th June 2025 Dividend yield will be 5.3%, which is higher than the industry average of 1.9%. Sustainability & Growth Dividend is not adequately covered by earnings (94% earnings payout ratio) nor is it covered by cash flows (125% cash payout ratio). The dividend has increased by an average of 24% per year over the past 10 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to grow by 4.9% to bring the payout ratio under control. EPS is expected to grow by 41% over the next 3 years, which is sufficient to bring the dividend into a sustainable range. Reported Earnings • Apr 26
First quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind First quarter 2025 results: EPS: CN¥0.45 (up from CN¥0.43 in 1Q 2024). Revenue: CN¥1.18b (down 3.5% from 1Q 2024). Net income: CN¥284.9m (up 6.8% from 1Q 2024). Profit margin: 24% (up from 22% in 1Q 2024). The increase in margin was driven by lower expenses. Revenue missed analyst estimates by 2.6%. Earnings per share (EPS) exceeded analyst estimates by 6.6%. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has increased by 20% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Apr 26
Jiang Zhong Pharmaceutical Co.,Ltd, Annual General Meeting, May 16, 2025 Jiang Zhong Pharmaceutical Co.,Ltd, Annual General Meeting, May 16, 2025, at 14:00 China Standard Time. Location: The Company's Meeting Room, Nanchang, Jiangxi China Announcement • Mar 28
Jiang Zhong Pharmaceutical Co.,Ltd to Report Q1, 2025 Results on Apr 26, 2025 Jiang Zhong Pharmaceutical Co.,Ltd announced that they will report Q1, 2025 results on Apr 26, 2025 Reported Earnings • Mar 20
Full year 2024 earnings released: EPS: CN¥1.25 (vs CN¥1.12 in FY 2023) Full year 2024 results: EPS: CN¥1.25 (up from CN¥1.12 in FY 2023). Revenue: CN¥4.44b (up 1.0% from FY 2023). Net income: CN¥788.2m (up 11% from FY 2023). Profit margin: 18% (up from 16% in FY 2023). Revenue is forecast to grow 8.5% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 14% per year whereas the company’s share price has increased by 19% per year. Reported Earnings • Jan 25
Full year 2024 earnings released: EPS: CN¥1.25 (vs CN¥1.12 in FY 2023) Full year 2024 results: EPS: CN¥1.25 (up from CN¥1.12 in FY 2023). Revenue: CN¥4.44b (up 1.0% from FY 2023). Net income: CN¥784.9m (up 11% from FY 2023). Profit margin: 18% (up from 16% in FY 2023). Revenue is forecast to grow 7.7% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has increased by 23% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Dec 27
Jiang Zhong Pharmaceutical Co.,Ltd to Report Fiscal Year 2024 Results on Mar 20, 2025 Jiang Zhong Pharmaceutical Co.,Ltd announced that they will report fiscal year 2024 results on Mar 20, 2025 Reported Earnings • Oct 26
Third quarter 2024 earnings: Revenues and EPS in line with analyst expectations Third quarter 2024 results: EPS: CN¥0.23 (up from CN¥0.23 in 3Q 2023). Revenue: CN¥799.4m (down 5.1% from 3Q 2023). Net income: CN¥145.6m (up 2.2% from 3Q 2023). Profit margin: 18% (up from 17% in 3Q 2023). The increase in margin was driven by lower expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) were also in line with analyst expectations. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has increased by 25% per year, which means it is tracking significantly ahead of earnings growth. Upcoming Dividend • Oct 03
Upcoming dividend of CN¥0.50 per share Eligible shareholders must have bought the stock before 10 October 2024. Payment date: 10 October 2024. The company is paying out more than 100% of its earnings and cash flow. Trailing yield: 5.5%. Within top quartile of Chinese dividend payers (2.2%). Higher than average of industry peers (1.7%). Announcement • Sep 30
Jiang Zhong Pharmaceutical Co.,Ltd to Report Q3, 2024 Results on Oct 26, 2024 Jiang Zhong Pharmaceutical Co.,Ltd announced that they will report Q3, 2024 results on Oct 26, 2024 Valuation Update With 7 Day Price Move • Sep 30
Investor sentiment improves as stock rises 22% After last week's 22% share price gain to CN¥23.60, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 18x in the Pharmaceuticals industry in China. Total returns to shareholders of 138% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥21.54 per share. Major Estimate Revision • Sep 12
Consensus revenue estimates fall by 11% The consensus outlook for revenues in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from CN¥4.90b to CN¥4.35b. EPS estimate fell from CN¥1.39 to CN¥1.28 per share. Net income forecast to grow 15% next year vs 29% growth forecast for Pharmaceuticals industry in China. Consensus price target down from CN¥31.08 to CN¥28.41. Share price fell 13% to CN¥18.37 over the past week. Price Target Changed • Sep 12
Price target decreased by 8.6% to CN¥28.41 Down from CN¥31.08, the current price target is an average from 3 analysts. New target price is 55% above last closing price of CN¥18.37. Stock is down 6.8% over the past year. The company is forecast to post earnings per share of CN¥1.28 for next year compared to CN¥1.12 last year. Reported Earnings • Aug 22
Second quarter 2024 earnings released: EPS: CN¥0.35 (vs CN¥0.32 in 2Q 2023) Second quarter 2024 results: EPS: CN¥0.35 (up from CN¥0.32 in 2Q 2023). Revenue: CN¥945.1m (down 3.7% from 2Q 2023). Net income: CN¥222.0m (up 7.7% from 2Q 2023). Profit margin: 24% (up from 21% in 2Q 2023). The increase in margin was driven by lower expenses. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has increased by 24% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Jun 28
Jiang Zhong Pharmaceutical Co.,Ltd to Report First Half, 2024 Results on Aug 22, 2024 Jiang Zhong Pharmaceutical Co.,Ltd announced that they will report first half, 2024 results on Aug 22, 2024 Buy Or Sell Opportunity • Jun 13
Now 25% undervalued Over the last 90 days, the stock has risen 8.3% to CN¥24.79. The fair value is estimated to be CN¥32.94, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 20% over the last 3 years. Earnings per share has grown by 14%. Revenue is forecast to grow by 35% in 2 years. Earnings are forecast to grow by 30% in the next 2 years. Buy Or Sell Opportunity • May 27
Now 20% overvalued after recent price rise Over the last 90 days, the stock has risen 15% to CN¥26.58. The fair value is estimated to be CN¥22.07, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 20% over the last 3 years. Earnings per share has grown by 14%. Revenue is forecast to grow by 35% in 2 years. Earnings are forecast to grow by 31% in the next 2 years. Buy Or Sell Opportunity • May 06
Now 21% overvalued after recent price rise Over the last 90 days, the stock has risen 22% to CN¥27.30. The fair value is estimated to be CN¥22.58, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 20% over the last 3 years. Earnings per share has grown by 13%. Revenue is forecast to grow by 36% in 2 years. Earnings are forecast to grow by 33% in the next 2 years. Reported Earnings • Apr 30
First quarter 2024 earnings released: EPS: CN¥0.43 (vs CN¥0.38 in 1Q 2023) First quarter 2024 results: EPS: CN¥0.43 (up from CN¥0.38 in 1Q 2023). Revenue: CN¥1.23b (down 6.8% from 1Q 2023). Net income: CN¥266.8m (up 11% from 1Q 2023). Profit margin: 22% (up from 18% in 1Q 2023). The increase in margin was driven by lower expenses. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has increased by 34% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Apr 29
Jiang Zhong Pharmaceutical Co.,Ltd, Annual General Meeting, May 17, 2024 Jiang Zhong Pharmaceutical Co.,Ltd, Annual General Meeting, May 17, 2024, at 14:30 China Standard Time. Location: The Company's Meeting Room, Nanchang, Jiangxi China Announcement • Mar 29
Jiang Zhong Pharmaceutical Co.,Ltd to Report Q1, 2024 Results on Apr 27, 2024 Jiang Zhong Pharmaceutical Co.,Ltd announced that they will report Q1, 2024 results on Apr 27, 2024 Reported Earnings • Mar 23
Full year 2023 earnings: EPS in line with analyst expectations despite revenue beat Full year 2023 results: EPS: CN¥1.12 (up from CN¥0.94 in FY 2022). Revenue: CN¥4.39b (up 15% from FY 2022). Net income: CN¥708.3m (up 19% from FY 2022). Profit margin: 16% (in line with FY 2022). Revenue exceeded analyst estimates by 2.0%. Earnings per share (EPS) were mostly in line with analyst estimates. Revenue is forecast to grow 12% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has increased by 29% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Dec 29
Jiang Zhong Pharmaceutical Co.,Ltd to Report Fiscal Year 2023 Results on Mar 23, 2024 Jiang Zhong Pharmaceutical Co.,Ltd announced that they will report fiscal year 2023 results on Mar 23, 2024 Reported Earnings • Nov 01
Third quarter 2023 earnings released: EPS: CN¥0.23 (vs CN¥0.18 in 3Q 2022) Third quarter 2023 results: EPS: CN¥0.23 (up from CN¥0.18 in 3Q 2022). Revenue: CN¥842.5m (down 14% from 3Q 2022). Net income: CN¥142.5m (up 27% from 3Q 2022). Profit margin: 17% (up from 12% in 3Q 2022). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has increased by 21% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Sep 30
Jiang Zhong Pharmaceutical Co.,Ltd to Report Q3, 2023 Results on Oct 28, 2023 Jiang Zhong Pharmaceutical Co.,Ltd announced that they will report Q3, 2023 results on Oct 28, 2023 Reported Earnings • Aug 24
Second quarter 2023 earnings released: EPS: CN¥0.32 (vs CN¥0.33 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.32 (down from CN¥0.33 in 2Q 2022). Revenue: CN¥981.2m (up 1.1% from 2Q 2022). Net income: CN¥206.2m (down 1.2% from 2Q 2022). Profit margin: 21% (in line with 2Q 2022). Over the last 3 years on average, earnings per share has increased by 11% per year whereas the company’s share price has increased by 13% per year. Board Change • Apr 12
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 4 independent directors. 5 non-independent directors. Independent Director Weidong Zhang was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Buying Opportunity • Mar 19
Now 21% undervalued Over the last 90 days, the stock is up 23%. The fair value is estimated to be CN¥23.70, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has grown by 7.8%. Reported Earnings • Mar 14
Full year 2022 earnings released: EPS: CN¥0.94 (vs CN¥0.80 in FY 2021) Full year 2022 results: EPS: CN¥0.94 (up from CN¥0.80 in FY 2021). Revenue: CN¥3.81b (up 33% from FY 2021). Net income: CN¥596.1m (up 18% from FY 2021). Profit margin: 16% (down from 18% in FY 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has increased by 21% per year, which means it is tracking significantly ahead of earnings growth. Board Change • Nov 16
Less than half of directors are independent There are 6 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 4 independent directors. 5 non-independent directors. Independent Director Weidong Zhang was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Reported Earnings • Oct 25
Third quarter 2022 earnings released: EPS: CN¥0.18 (vs CN¥0.23 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.18 (down from CN¥0.23 in 3Q 2021). Revenue: CN¥973.5m (up 45% from 3Q 2021). Net income: CN¥112.6m (down 23% from 3Q 2021). Profit margin: 12% (down from 22% in 3Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 6% per year whereas the company’s share price has increased by 7% per year. Announcement • Oct 18
China Resources Pharmaceutical Group Limited Provides Earnings Forecasts for the Nine Months Ended 30 September 2022 China Resources Pharmaceutical Group Limited provided earnings forecasts for the nine months ended 30 September 2022. For the nine months, the total operating income of Jiangzhong Pharmaceutical is expected to increase by approximately 45% year-on- year, and the net profit attributable to shareholders to increase by approximately 12% year-on-year. Reported Earnings • Aug 20
Second quarter 2022 earnings released: EPS: CN¥0.33 (vs CN¥0.24 in 2Q 2021) Second quarter 2022 results: EPS: CN¥0.33 (up from CN¥0.24 in 2Q 2021). Revenue: CN¥970.1m (up 65% from 2Q 2021). Net income: CN¥208.6m (up 42% from 2Q 2021). Profit margin: 22% (down from 25% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 12% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Apr 27
First quarter 2022 earnings released: EPS: CN¥0.29 (vs CN¥0.25 in 1Q 2021) First quarter 2022 results: EPS: CN¥0.29 (up from CN¥0.25 in 1Q 2021). Revenue: CN¥930.7m (up 37% from 1Q 2021). Net income: CN¥183.7m (up 15% from 1Q 2021). Profit margin: 20% (down from 24% in 1Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has increased by 2% per year. Reported Earnings • Oct 28
Third quarter 2021 earnings released: EPS CN¥0.23 (vs CN¥0.20 in 3Q 2020) The company reported a solid third quarter result with improved earnings and revenues, although profit margins were flat. Third quarter 2021 results: Revenue: CN¥671.6m (up 17% from 3Q 2020). Net income: CN¥145.3m (up 14% from 3Q 2020). Profit margin: 22% (in line with 3Q 2020). Over the last 3 years on average, earnings per share has increased by 3% per year and the company’s share price has also increased by 3% per year. Announcement • Sep 24
Jiang Zhong Pharmaceutical Co.,Ltd (SHSE:600750) entered in a contract to acquire 36% stake in Jincheng Haisi Pharmacy Limited Company from Jinneng Holding Equipment Manufacturing Group Co., Ltd. and Jincheng Wangtai Technology Industry and Trade Co., Ltd for approximately CNY 120 million. Jiang Zhong Pharmaceutical Co.,Ltd (SHSE:600750) entered in a contract to acquire 36% stake in Jincheng Haisi Pharmacy Limited Company from Jinneng Holding Equipment Manufacturing Group Co., Ltd. and Jincheng Wangtai Technology Industry and Trade Co., Ltd for approximately CNY 120 million on September 17, 2021. Jinneng Holding Equipment Manufacturing Group Co., Ltd. will transfer 25.7102% of the target company's equity, Jincheng Wangtai Technology Industry and Trade Co., Ltd will transfer 10.2898% of the target company's equity. The transaction has been approved by Board of Directors of Jiang zhong Pharmaceutical Co., Ltd. Reported Earnings • Aug 19
Second quarter 2021 earnings released: EPS CN¥0.24 (vs CN¥0.22 in 2Q 2020) The company reported a decent second quarter result with improved earnings and profit margins, although revenues were weaker. Second quarter 2021 results: Revenue: CN¥588.7m (down 7.0% from 2Q 2020). Net income: CN¥147.2m (up 6.2% from 2Q 2020). Profit margin: 25% (up from 22% in 2Q 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has increased by 5% per year. Valuation Update With 7 Day Price Move • Jun 30
Investor sentiment improved over the past week After last week's 17% share price gain to CN¥13.25, the stock trades at a trailing P/E ratio of 16.8x. Average trailing P/E is 32x in the Pharmaceuticals industry in China. Negligible returns to shareholders over past year. Announcement • Jun 18
Jiang Zhong Pharmaceutical Co.,Ltd (SHSE:600750) announces an Equity Buyback for 7,000,000 shares, representing 1.11% for CNY 115.5 million. Jiang Zhong Pharmaceutical Co.,Ltd (SHSE:600750) announces a share repurchase program. Under the program, the company will repurchase up to 7,000,000 shares, representing 1.11% of its share capital. The shares will be repurchased at a price not more than CNY 16.50 per share. The repurchased shares will be used for equity incentives plans. The repurchase program will be valid for a period of 12 months. Reported Earnings • Apr 25
First quarter 2021 earnings released: EPS CN¥0.25 (vs CN¥0.21 in 1Q 2020) The company reported a solid first quarter result with improved earnings and revenues, although profit margins were weaker. First quarter 2021 results: Revenue: CN¥677.5m (up 29% from 1Q 2020). Net income: CN¥159.3m (up 21% from 1Q 2020). Profit margin: 24% (down from 25% in 1Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. Reported Earnings • Mar 20
Full year 2020 earnings released: EPS CN¥0.75 (vs CN¥0.73 in FY 2019) The company reported a decent full year result with improved earnings, although revenues and profit margins were flat. Full year 2020 results: Revenue: CN¥2.44b (flat on FY 2019). Net income: CN¥473.7m (up 2.2% from FY 2019). Profit margin: 19% (in line with FY 2019). Over the last 3 years on average, earnings per share has increased by 4% per year whereas the company’s share price has fallen by 1% per year. Is New 90 Day High Low • Jan 26
New 90-day low: CN¥10.34 The company is down 12% from its price of CN¥11.71 on 28 October 2020. The Chinese market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 3.0% over the same period. Announcement • Jan 22
Jiang Zhong Pharmaceutical Co.,Ltd to Report Fiscal Year 2020 Results on Mar 20, 2021 Jiang Zhong Pharmaceutical Co.,Ltd announced that they will report fiscal year 2020 results on Mar 20, 2021 Is New 90 Day High Low • Dec 12
New 90-day low: CN¥10.89 The company is down 9.0% from its price of CN¥11.98 on 11 September 2020. The Chinese market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 7.0% over the same period. Is New 90 Day High Low • Oct 30
New 90-day low: CN¥11.55 The company is down 13% from its price of CN¥13.32 on 31 July 2020. The Chinese market is down 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 9.0% over the same period. Reported Earnings • Oct 28
Third quarter earnings released Over the last 12 months the company has reported total profits of CN¥480.0m, down 3.6% from the prior year. Total revenue was CN¥2.48b over the last 12 months, up 14% from the prior year. Is New 90 Day High Low • Sep 25
New 90-day low: CN¥11.81 The company is down 4.0% from its price of CN¥12.24 on 24 June 2020. The Chinese market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 4.0% over the same period. Announcement • Jul 09
Jiangzhong Pharmaceutical Co., Ltd to Report First Half, 2020 Results on Aug 26, 2020 Jiangzhong Pharmaceutical Co., Ltd announced that they will report first half, 2020 results on Aug 26, 2020